Supplementary Information

Gold-Catalyzed Amination of *in situ* Formed Alkyl Gold Species with p-Quinonediimines as N-Sources

Xinyu Pan, 1 Yusuf Abdulla, 2 Ming Bao, *1 and Xinfang Xu *1

*Emails: baoming@zstu.edu.cn; xuxinfang@zstu.edu.cn

Table of Contents

1. General Information	S2
2. General Procedure for the Gold-Catalyzed Amination Reaction	S2-S12
3. General Procedure for Scale Up	S12-S13
4. Synthetic Applications	S13-S16
5. ¹ H and ¹³ C NMR Spectra for Compounds 3, 4, 5, 6, 7 and 9	S17-S40
6. Single-Crystal X-ray Diffraction of 3g	S41
7. References	S42

¹School of Chemistry and Chemical Engineering, Zhejiang Sci-Tech University, Hangzhou 310018, China.

²College of Chemistry and Environmental Science, Laboratory of Xinjiang Native Medicinal and Edible Plant Resources Chemistry, Kashi University, Kashi 844000, China.

General Information

All reactions were carried out in oven-dried glassware. Solvents were dried by the standard methods. Gold catalyst Me₃(OMe)tBuXPhosAuNTf₂ and starting material p-quinonediimines **2** were prepared according to previously published procedure, and had physical and spectral properties identical to those earlier reported. Flash column chromatography was performed using silica gel (300-400 mesh). Analytical thin-layer chromatography was performed using glass plates pre-coated with 200-300 mesh silica gel impregnated with a fluorescent indicator (254 nm). H NMR and NMR spectra were recorded in CDCl₃ or DMSO- d_6 on a 400 MHz spectrometer; Chemical shifts were reported in ppm with the solvent signal as reference, and coupling constants (J) were given in Hertz. The peak information was described as: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, comp = composite. High-resolution mass spectra (HRMS) were recorded on a commercial apparatus (ESI or CI Source).

General Procedure for the Gold-Catalyzed Amination Reaction

To a 10-mL oven-dried test tube containing a magnetic stirring bar, *p*-quinonediimines **2** (0.15 mmol, 1.5 equiv.), Et₃N (1.0 mg, 10 mol%), and Me₃(OMe)*t*BuXPhosAuNTf₂ (5.0 mg, 5.0 mol%) in DCE (1.0 mL), was added a solution of propargyl amides **1** (0.1 mmol, 1.0 equiv.) in DCE (1.0 mL) at room temperature under argon atmosphere. The resulting reaction mixture was stirred for 6 h under these conditions. When the reaction was completed (monitored by TLC), the solvent was evaporated in vacuo and the residue was purified by flash column chromatography on silica gel (hexanes/ethyl acetate = 6:1 to 3:1) to afford the pure products **3** in good to high yields.

4-Methyl-*N***-(5-methylene-2-phenyl-4,5-dihydrooxazol-4-yl)**-*N***-(4-((4-methylphen yl)sulfonamido)phenyl)benzenesulfonamide (3a)**. White solid, mp: 158-160 °C, 47.6 mg, 83% yield, ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.81 (d, J = 7.1 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 7.4 Hz, 1H), 7.49 (d, J = 8.5 Hz, 2H), 7.40 (t, J = 7.7 Hz, 2H), 7.24 (d, J = 7.9 Hz, 2H), 7.08 (d, J = 8.0 Hz, 2H), 6.97 (t, J = 2.5 Hz, 1H), 6.88 – 6.81 (m, 5H), 4.99 (t, J = 2.8 Hz, 1H), 4.81 – 4.77 (m, 1H), 2.45 (s, 3H), 2.34 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 164.3, 156.1, 144.1, 143.9, 137.2, 136.5, 135.9, 133.2, 132.7, 131.7, 129.7, 129.4, 128.7, 128.49, 128.45, 127.3, 126.0, 121.0, 90.3, 81.2, 21.8, 21.7; HRMS (TOF MS ESI⁺) calculated for C₃₀H₂₈N₃O₅S₂ [M+H]⁺: 574.1465, found 574.1456.

N-(5-Methylene-2-phenyl-4,5-dihydrooxazol-4-yl)-*N*-(4-(phenylsulfonamido)phen yl)benzenesulfonamide (3b). White solid, mp: 85-87 °C, 48.5 mg, 78% yield, 1 H NMR (400 MHz, CDCl₃) (δ, ppm) 7.77 (t, J = 7.9 Hz, 4H), 7.63 – 7.55 (m, 3H), 7.54 – 7.48 (m, 1H), 7.47 – 7.42 (m, 2H), 7.42 – 7.36 (m, 4H), 7.29 – 7.27 (m, 1H), 7.25 – 7.23 (m, 1H), 6.97 (t, J = 2.4 Hz, 1H), 6.84 (s, 4H), 4.99 (t, J = 2.9 Hz, 1H), 4.79 (t, J = 2.7 Hz, 1H); 13 C NMR (100 MHz, CDCl₃) (δ, ppm) 164.4, 155.9, 139.3, 138.6, 137.3, 133.13, 133.10, 133.06, 132.7, 131.5, 129.0, 128.69, 128.67, 128.4, 128.3, 127.2, 125.8, 121.0, 90.4, 81.1; HRMS (TOF MS ESI⁺) calculated for C₂₈H₂₄N₃O₅S₂ [M+H]⁺: 546.1152, found 546.1142.

4-Methoxy-*N*-(**4-((4-methoxyphenyl)sulfonamido)phenyl)**-*N*-(**5-methylene-2-phen yl-4,5-dihydrooxazol-4-yl)benzenesulfonamide (3c)**. White solid, mp: 109-111 °C, 51.4 mg, 85% yield, ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.79 (d, J = 7.1 Hz, 2H), 7.66 (d, J = 8.9 Hz, 2H), 7.56 (d, J = 9.0 Hz, 2H), 7.53 – 7.48 (m, 1H), 7.42 – 7.36 (m, 2H), 7.09 (s, 1H), 6.95 (t, J = 2.5 Hz, 1H), 6.92 – 6.87 (m, 2H), 6.87 – 6.81 (m, 4H), 6.77 (d, J = 9.0 Hz, 2H), 4.97 (t, J = 2.8 Hz, 1H), 4.78 (t, J = 2.7 Hz, 1H), 3.88 (s, 3H), 3.80 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 164.3, 163.3, 163.2, 156.1, 137.3, 133.1, 132.7, 131.7, 131.0, 130.6, 130.4, 129.5, 128.7, 128.4, 125.9, 120.8, 114.4, 114.2, 113.8, 90.3, 81.2, 55.7; HRMS (TOF MS ESI⁺) calculated for C₃₀H₂₈N₃O₇S₂ [M+H]⁺: 606.1363, found 606.1355.

4-Bromo-*N***-(4-((4-bromophenyl)sulfonamido)phenyl)**-*N***-(5-methylene-2-phenyl-4 ,5-dihydrooxazol-4-yl)benzenesulfonamide (3d)**. White solid, mp: 97-99 °C, 56.8 mg, 81% yield, 1 H NMR (400 MHz, CDCl₃) (δ , ppm) 7.80 (d, J = 8.0 Hz, 2H), 7.66 –

7.58 (m, 4H), 7.57 – 7.53 (m, 1H), 7.47 – 7.39 (m, 6H), 7.14 (s, 1H), 6.95 (s, 1H), 6.90 – 6.83 (m, 4H), 5.02 (t, J = 2.9 Hz, 1H), 4.81 (t, J = 2.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 164.6, 155.7, 138.4, 137.7, 137.0, 133.1, 133.0, 132.4, 132.1, 131.7, 130.0, 128.8, 128.7, 128.5, 128.4, 128.2, 125.7, 121.2, 90.7, 81.3; HRMS (TOF MS ESI⁺) calculated for C₂₈H₂₁NaBr₂N₃O₅S₂ [M+Na]⁺: 725.9161, found 725.9156.

N-(5-Methylene-2-phenyl-4,5-dihydrooxazol-4-yl)-4-(trifluoromethyl)-*N*-(4-((4-(trifluoromethyl)phenyl)sulfonamido)phenyl)benzenesulfonamide (3e). White solid, mp: 133-135 °C, 44.7 mg, 59% yield, ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 7.93 (d, J = 8.2 Hz, 2H), 7.78 (d, J = 7.0 Hz, 2H), 7.73 (d, J = 8.3 Hz, 4H), 7.58 – 7.52 (m, 3H), 7.45 – 7.38 (m, 2H), 7.10 (s, 1H), 6.98 (t, J = 2.4 Hz, 1H), 6.89 (s, 4H), 5.03 (t, J = 2.9 Hz, 1H), 4.83 (t, 1H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 164.8, 155.6, 143.0, 142.3, 136.9, 135.0 (q, J = 17.5 Hz), 134.7 (q, J = 275 Hz), 133.13, 133.06, 131.7, 128.9, 128.8, 128.4, 127.8, 126.2 (q, J = 3.4 Hz), 125.9 (q, J = 3.9 Hz), 125.6, 121.3, 90.9, 81.4.; ¹⁹F NMR (376 MHz, CDCl₃) (δ, ppm) -63.57, -63.66; HRMS (TOF MS ESI⁺) calculated for C₃₀H₂₂F₆N₃O₅S₂ [M+H]⁺: 682.0900, found 682.0888.

N-(5-Methylene-2-phenyl-4,5-dihydrooxazol-4-yl)-*N*-(4-(naphthalene-2-sulfonam ido)phenyl)naphthalene-2-sulfonamide (3f). White solid, mp: 104-106 °C, 55.5 mg, 77% yield, 1 H NMR (400 MHz, CDCl₃) (δ, ppm) 8.27 (s, 1H), 8.21 (s, 1H), 7.89 – 7.81 (m, 3H), 7.77 – 7.69 (m, 6H), 7.66 – 7.58 (m, 3H), 7.58 – 7.46 (m, 3H), 7.33 (t, *J* = 7.7 Hz, 2H), 7.06 (s, 1H), 7.02 (t, *J* = 2.5 Hz, 1H), 6.85 (s, 4H), 4.95 (t, *J* = 2.9 Hz, 1H), 4.79 (t, *J* = 2.7 Hz, 1H); 13 C NMR (100 MHz, CDCl₃) (δ, ppm) 164.4, 155.9, 137.2, 136.3, 135.8, 135.1, 135.0, 133.2, 132.7, 132.1, 132.0, 131.7, 129.9, 129.5, 129.4, 129.2, 129.0, 128.9, 128.8, 128.6, 128.4, 128.0, 128.0, 127.8, 127.4, 125.8, 123.6, 122.2, 120.9, 90.4, 81.4; HRMS (TOF MS ESI⁺) calculated for $C_{36}H_{27}NaN_3O_5S_2$ [M+Na]⁺: 668.1284, found 668.1271.

4-Methyl-*N***-(5-methylene-2-**(*p***-tolyl)-4,5-dihydrooxazol-4-yl)-***N***-(4-((4-methylphe nyl)sulfonamido)phenyl)benzenesulfonamide (3g)**. White solid, mp: 95-97 °C, 56.4 mg, 96% yield, 1 H NMR (400 MHz, CDCl₃) (δ , ppm) 7.69 (d, J = 7.9 Hz, 2H), 7.63 (d, J = 7.9 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H), 7.24 – 7.16 (m, 5H), 7.07 (d, J = 8.0 Hz, 2H), 6.94 (s, 1H), 6.87 – 6.81 (m, 4H), 4.96 (t, J = 2.8 Hz, 1H), 4.76 (t, J = 2.5 Hz, 1H), 2.44 (s, 3H), 2.39 (s, 3H), 2.33 (s, 3H); 13 C NMR (100 MHz, CDCl₃) (δ , ppm) 164.4, 156.1, 144.0, 143.8, 143.4, 137.2, 136.5, 135.8, 133.1, 131.6, 129.6, 129.4,

129.3, 128.4, 128.4, 127.2, 123.1, 121.0, 90.1, 81.2, 21.79, 21.75, 21.6; HRMS (TOF MS ESI⁺) calculated for $C_{31}H_{30}N_3O_5S_2$ [M+H]⁺: 588.1621, found 588.1612.

4-Methoxy-*N***-(4-((4-methoxyphenyl)sulfonamido)phenyl)**-*N***-(5-methylene-2-(p-to lyl)-4,5-dihydrooxazol-4-yl)benzenesulfonamide (3h)**. White solid, mp: 98-100 °C, 57.6 mg, 93% yield, ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.71 – 7.67 (m, 4H), 7.54 (d, J = 8.9 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 6.97 – 6.84 (m, 5H), 6.83 – 6.72 (m, 4H), 6.44 (s, 1H), 4.97 (t, J = 2.7 Hz, 1H), 4.77 (t, J = 2.7 Hz, 1H), 3.89 (s, 3H), 3.83 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 164.4, 163.3, 163.2, 156.2, 143.4, 137.2, 133.2, 131.9, 131.0, 130.6, 130.3, 129.5, 129.4, 128.4, 123.1, 120.9, 114.2, 113.8, 90.1, 81.2, 55.7, 21.8; HRMS (TOF MS ESI⁺) calculated for $C_{31}H_{30}N_{3}O_{7}S_{2}$ [M+H]⁺: 620.1520, found 620.1524.

N-(2-(4-Chlorophenyl)-5-methylene-4,5-dihydrooxazol-4-yl)-4-methyl-*N*-(4-((4-methylphenyl)sulfonamido)phenyl)benzenesulfonamide (3i). White solid, mp: 171-173 °C, 49.2 mg, 81% yield, ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 7.77 – 7.71 (m, 2H), 7.62 (d, J = 8.1 Hz, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.40 – 7.36 (m, 2H), 7.25 – 7.21 (m, 2H), 7.11 (d, J = 8.1 Hz, 2H), 6.95 (t, J = 2.4 Hz, 1H), 6.88 – 6.77 (m, 5H),

5.00 (t, J = 2.9 Hz, 1H), 4.80 (t, J = 2.6 Hz, 1H), 2.45 (s, 3H), 2.36 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 163.4, 156.0, 144.2, 143.9, 139.1, 137.3, 136.5, 136.0, 133.2, 131.6, 129.8, 129.6,7 129.4, 129.1, 128.4, 127.3, 124.4, 120.9, 90.6, 81.2, 21.8, 21.7; HRMS (TOF MS ESI⁺) calculated for C₃₀H₂₇ClN₃O₅S₂ [M+H]⁺: 608.1075, found 608.1068.

N-(2-(4-Bromophenyl)-5-methylene-4,5-dihydrooxazol-4-yl)-4-methyl-*N*-(4-((4-methylphenyl)sulfonamido)phenyl)benzenesulfonamide (3j). White solid, mp: 87-89 °C, 56.6 mg, 87% yield, 1 H NMR (400 MHz, CDCl₃) (δ, ppm) 7.68 – 7.64 (m, 2H), 7.63 – 7.59 (m, 2H), 7.56 – 7.51 (m, 4H), 7.23 (d, J = 8.1 Hz, 2H), 7.16 (s, 1H), 7.10 (d, J = 8.1 Hz, 2H), 6.94 (m, J = 2.5 Hz, 1H), 6.84 (s, 4H), 4.99 (t, J = 2.9 Hz, 1H), 4.80 (t, J = 2.9 Hz, 1H), 2.44 (s, 3H), 2.36 (s, 3H); 13 C NMR (100 MHz, CDCl₃) (δ, ppm) 163.5, 155.9, 144.2, 143.9, 137.3, 136.4, 135.9, 133.1, 132.0, 131.5, 129.9, 129.7, 129.4, 128.4, 127.6, 127.3, 24.8, 120.8, 90.6, 81.2, 21.8, 21.7; HRMS (TOF MS ESI⁺) calculated for C₃₀H₂₇BrN₃O₅S₂ [M+H]⁺: 652.0570, found 652.0563.

N-(2-(4-Cyanophenyl)-5-methylene-4,5-dihydrooxazol-4-yl)-4-methyl-*N*-(4-((4-m ethylphenyl)sulfonamido)phenyl)benzenesulfonamide (3k). White solid, mp: 89-91 °C, 55.6 mg, 93% yield, 1 H NMR (400 MHz, CDCl₃) (δ, ppm) 7.91 (d, J = 8.4 Hz, 2H), 7.69 (d, J = 8.5 Hz, 2H), 7.60 – 7.56 (m, 4H), 7.25 – 7.21 (m, 3H), 7.15 (d, J = 8.0 Hz, 2H), 6.98 (t, J = 1.8 Hz, 1H), 6.88 – 6.78 (m, 4H), 5.03 (t, J = 3.0 Hz, 1H), 4.83 (t, J = 3.0 Hz, 1H), 2.45 (s, 3H), 2.37 (s, 3H); 13 C NMR (100 MHz, CDCl₃) (δ,

ppm) 162.7, 155.6, 144.2, 144.1, 137.5, 136.3, 136.0, 133.0, 132.4, 131.2, 130.0, 129.7, 129.4, 129.0, 128.4, 127.3, 120.5, 118.0, 116.1, 91.3, 81.2, 21.8, 21.7; HRMS (TOF MS ESI⁺) calculated for C₃₁H₂₇N₄O₅S₂ [M+H]⁺: 599.1417, found 599.1412.

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

Methyl 4-(4-((4-methyl-*N***-(4-((4-methylphenyl)sulfonamido)phenyl)phenyl) sulfonamido)-5-methylene-4,5-dihydrooxazol-2-yl)benzoate (3l)**. White solid, mp: 95-96 °C, 53.6 mg, 85% yield, ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 8.06 (d, J = 8.1 Hz, 2H), 7.87 (d, J = 8.1 Hz, 2H), 7.62 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 8.0 Hz, 2H), 7.26 – 7.22 (m, 2H), 7.10 (d, J = 8.0 Hz, 2H), 7.00 – 6.96 (m, 1H), 6.91 – 6.81 (m, 5H), 5.02 (t, J = 2.9 Hz, 1H), 4.82 (t, J = 2.8 Hz, 1H), 3.94 (s, 3H), 2.45 (s, 3H), 2.35 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 166.3, 163.5, 155.9, 144.2, 144.0, 137.3, 136.4, 136.0, 133.7, 133.1, 129.8, 129.7, 129.4, 128.5, 128.4, 127.3, 120.9, 90.8, 81.2, 52.6, 21.8, 21.7; HRMS (TOF MS ESI⁺) calculated for C₃₂H₃₀N₃O₇S₂ [M+H]⁺: 632.1520, found 632.1514.

N-(2-([1,1'-Biphenyl]-4-yl)-5-methylene-4,5-dihydrooxazol-4-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-yl)-5-methylene-4,5-dihydrooxazol-4-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl))) 4-methyl-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-yl)-4-methyl-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-yl)-4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-*N*-(4-((4-(1,1'-Biphenyl)))) 4-methyl-*N*-(4-(4-(4,1'-Biphenyl))) 4-methyl-*N*-(4-(4-(4,1'-Biphenyl))) 4-methyl-*N*-(4-(4-(4,1'-Biphenyl))) 4-methyl-*N*-(4-(4-(4,1'-Biphenyl))) 4-methyl-*N*-(4-(4-(4,1'-Biphenyl))) 4-methyl-*N*-(4-(4,1'-Biphenyl)) 4-methyl-*N*-(4-(4,1'-Biphen

133.2, 131.7, 129.7, 129.3, 129.1, 129.0, 128.4, 128.4, 127.3, 127.3, 127.2, 124.7, 121.0, 90.3, 81.3, 21.8, 21.6; HRMS (TOF MS ESI⁺) calculated for C₃₆H₃₂N₃O₅S₂ [M+H]⁺: 650.1778, found 650.1765.

N-(2-(Benzo[*d*][1,3]dioxol-5-yl)-5-methylene-4,5-dihydrooxazol-4-yl)-4-methyl-*N*-(4-((4-methylphenyl)sulfonamido)phenyl)benzenesulfonamide (3n). White solid, mp: 82-84 °C, 54.9 mg, 89% yield, ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 7.63 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.38 – 7.34 (m, 1H), 7.26 – 7.21 (m, 3H), 7.13 (d, J = 8.1 Hz, 2H), 6.94 – 6.91 (m, 1H), 6.86 – 6.77 (m, 6H), 6.03 (s, 2H), 4.95 (t, J = 2.8 Hz, 1H), 4.76 (t, J = 2.6 Hz, 1H), 2.45 (s, 3H), 2.37 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 163.8, 156.2, 151.5, 148.0, 144.2, 143.8, 137.2, 136.6, 136.0, 133.2, 131.8, 129.7, 129.3, 128.4, 127.3, 124.0, 121.0, 119.8, 108.4, 108.3, 102.0, 90.0, 81.1, 21.8, 21.7; HRMS (TOF MS ESI⁺⁾ calculated for C₃₁H₂₈N₃O₇S₂ [M+H]⁺: 618.1363, found 618.1356.

N-(2-(*tert*-Butyl)-5-methylene-4,5-dihydrooxazol-4-yl)-4-methyl-*N*-(4-((4-methylp henyl)sulfonamido)phenyl)benzenesulfonamide (3o). White solid, mp: 76-78 °C, 44.3 mg, 80% yield, ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 7.64 – 7.60 (m, 4H), 7.32 (s, 1H), 7.20 (d, J = 8.1 Hz, 4H), 6.91 (d, J = 8.8 Hz, 2H), 6.80 (d, J = 8.7 Hz, 2H), 6.73 (t, J = 2.3 Hz, 1H), 4.81 (t, J = 2.7 Hz, 1H), 4.66 (t, J = 2.5 Hz, 1H), 2.42 (s, 3H), 2.38 (s, 3H), 0.95 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 174.8, 156.7, 144.2, 143.8, 137.4, 136.6, 136.0, 133.5, 131.1, 129.8, 129.3, 128.3, 127.3, 120.3, 89.4, 80.5,

33.3, 27.0, 21.7, 21.6; HRMS (TOF MS ESI $^+$) calculated for $C_{28}H_{32}N_3O_5S_2$ [M+H] $^+$: 554.1778, found 554.1773.

4-Methyl-*N*-(**2**-(**1**-methyl-1*H*-pyrrol-**2**-yl)-**5**-methylene-**4**,**5**-dihydrooxazol-**4**-yl)-*N* -(**4**-((**4**-methylphenyl)sulfonamido)phenyl)benzenesulfonamide (**3p**). White solid, mp: 73-75 °C, 43.2 mg, 75% yield, ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.64 (d, J = 8.0 Hz, 2H), 7.52 (d, J = 7.9 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 8.1 Hz, 2H), 6.95 (s, 1H), 6.85 – 6.80 (m, 6H), 6.66 (d, J = 3.5 Hz, 1H), 6.13 – 6.06 (m, 1H), 4.87 (t, J = 2.7 Hz, 1H), 4.66 (t, J = 2.5 Hz, 1H), 3.78 (s, 3H), 2.43 (s, 3H), 2.38 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 158.2, 154.7, 144.2, 143.7, 137.2, 136.7, 135.9, 133.0, 132.1, 129.8, 129.7, 129.1, 128.6, 127.3, 121.2, 118.8, 117.0, 108.5, 89.3, 81.6, 36.9, 21.74, 21.70; HRMS (TOF MS ESI⁺) calculated for C₂₉H₂₉N₄O₅S₂ [M+H]⁺: 577.1574, found 577.1566.

N-(2-(Benzofuran-2-yl)-5-methylene-4,5-dihydrooxazol-4-yl)-4-methyl-*N*-(4-((4-methylphenyl)sulfonamido)phenyl)benzenesulfonamide (3q). White solid, mp: 97-99 °C, 50.3 mg, 82% yield, ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 7.66 – 7.61 (m, 3H), 7.56 (d, J = 8.4 Hz, 1H), 7.51 (d, J = 8.3 Hz, 2H), 7.44 (t, J = 8.1 Hz, 1H), 7.33 – 7.29 (m, 2H), 7.26 – 7.22 (m, 2H), 7.05 (d, J = 8.1 Hz, 2H), 7.02 – 6.99 (m, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.70 (s, 1H), 5.08 (t, J = 3.0 Hz, 1H), 4.90 (t, J = 3.0 Hz, 1H), 2.44 (s, 3H), 2.27 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 157.0, 156.1, 155.5, 144.2, 144.0, 137.3 136.6, 136.0, 133.3, 131.6, 129.7,

129.6, 128.3, 127.8, 127.3, 127.0, 124.2, 122.7, 121.1, 113.2, 112.4, 91.0, 81.1, 21.8, 21.6; HRMS (TOF MS ESI^+) calculated for $C_{32}H_{28}N_3O_6S_2$ [M+H] $^+$: 614.1414, found 614.1407.

N-(2-(Benzo[*b*]thiophen-2-yl)-5-methylene-4,5-dihydrooxazol-4-yl)-4-methyl-*N*-(4 -((4-methylphenyl)sulfonamido)phenyl)benzenesulfonamide (3r). White solid, mp: 98-100 °C, 52.8 mg, 84% yield, ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 7.88 – 7.79 (m, 2H), 7.77 (s, 1H), 7.64 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 7.48 – 7.38 (m, 2H), 7.25 (d, J = 8.1 Hz, 3H), 7.02 (d, J = 8.1 Hz, 2H), 6.96 (t, J = 2.4 Hz, 1H), 6.92 – 6.80 (m, 4H), 5.03 (t, J = 2.9 Hz, 1H), 4.84 (t, J = 2.7 Hz, 1H), 2.46 (s, 3H), 2.25 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ, ppm) 160.4, 156.0, 144.1, 143.9, 141.8, 138.9, 137.3, 136.4, 135.9, 133.2, 131.7, 129.6, 129.4, 129.1, 128.5, 128.3, 127.2, 127.1, 125.4, 125.3, 122.7, 121.1, 90.7, 81.3, 21.8, 21.6; HRMS (TOF MS ESI⁺) calculated for C₃₂H₂₈N₃O₅S₃ [M+H]⁺: 630.1186, found 630.1183.

General Procedure for Scale Up

To a 50-mL oven-dried vial with a magnetic stirring bar, **2a** (1242 mg, 3.0 mmol), Et₃N (20.1 mg, 10 mol%), and Me₃(OMe)*t*BuXPhosAuNTf₂ (100 mg, 5.0 mol%) in DCE (10.0 mL), was added a solution of **1g** (346 mg, 2.0 mmol) in DCE (10.0 mL) at room temperature under argon atmosphere. The resulting reaction mixture was stirred for 6 h under these conditions. When the reaction was completed (monitored by TLC),

the solvent was evaporated in vacuo and the resulting residue was purified by flash column chromatography on silica gel (Hexanes : EtOAc = 3:1) to give 1.06 g pure product **3g** in 90% yield as white solid.

Synthetic Applications

Synthesis of 4: To a 10-mL oven-dried vial with a magnetic stirring bar, 3g (29.4 mg, 0.1 mmol), and Rh₂(OAc)₄ (0.4 mg, 0.001 mmol, 1.0 mol%) in DCM (1.0 mL), was added a solution of ethyl diazoacetate (57 mg, 0.5 mmol, 5.0 equiv) in DCM (1.0 mL) at 0 °C via syringe pump in 1 h, and the resulting solution was stirred at room temperature for 2 h. When the reaction was completed (monitored by TLC), the crude reaction mixture was purified by flash column chromatography on silica gel (Hexanes: EtOAc = 5:1) to afford pure product 4 as yellow solid (42.4 mg, 63% yield, 1:1 dr), mp: 115-118 °C. ¹H NMR (400 MHz, CDCl₃) (δ, ppm) 7.66 (s, 1H), 7.64 (s, 1H), 7.61 - 7.55 (m, 4H), 7.54 - 7.47 (m, 4H), 7.43 (s, 1H), 7.41 (s, 1H), 7.25 - 7.21(m, 3H), 7.20 (d, J = 8.3 Hz, 3H), 7.16 (s, 2H), 7.13 (s, 2H), 7.04 (s, 2H), 7.00 (s, 2H),6.98 (s, 1H), 6.96 (s, 1H), 6.86 (s, 2H), 6.84 (s, 2H), 6.34 (s, 2H), 4.15 (d, J = 7.2 Hz, 2H), 4.10 (d, J = 7.2 Hz, 2H), 2.45 (s, 3H), 2.41 (s, 3H), 2.40 (s, 3H), 2.38 (s, 3H), 2.36 (s, 3H), 2.34 (s, 3H), 2.27 – 2.23 (m, 1H), 2.22 – 2.19 (m, 1H), 2.09 (t, J = 7.1Hz, 1H), 1.91 (t, J = 7.3 Hz, 1H), 1.84 (d, J = 6.8 Hz, 1H), 1.81 – 1.78 (m, 1H), 1.26 (d, J = 7.2 Hz, 3H), 1.20 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 169.6, 168.2, 167.6, 166.8, 144.1, 143.9, 143.5, 143.2, 143.1, 137.2, 136.8, 136.6, 136.0, 135.9, 135.8, 133.0, 132.9, 132.4, 129.7, 129.7, 129.5, 129.4, 129.3, 129.0, 128.7, 128.5, 128.1, 127.3, 127.2, 127.1, 123.8, 123.7, 121.22, 121.19, 84.8, 72.0, 61.4, 61.2, 60.6, 28.0, 26.8, 21.8, 21.7, 21.6, 21.2, 16.0, 14.4, 14.3; HRMS (TOF MS ESI⁺) calculated for C₃₅H₃₆N₃O₇S₂ [M+H]⁺: 674.1989, found 674.1981.


Synthesis of 5: To a 10-mL oven-dried vial with a magnetic stirring bar, **3g** (58.8 mg, 0.10 mmol, 1.0 equiv.), and Cs₂CO₃ (61.8 mg, 0.20 mmol, 2.0 equiv.) in MeCN (2.0 mL), was added BnBr (25.5 mg, 0. 15 mmol, 1.5 equiv.) at 30 °C, and the reaction mixture was stirred for 6 h under these conditions. When the reaction was completed (monitored by TLC), the crude reaction mixture was purified by column chromatography on silica gel (Hexanes : EtOAc = 3:1) to give 57.6 mg pure product **5** in 85% yield as white solid, mp: 96-98 °C. ¹H NMR (400 MHz, CDCl₃) (8, ppm) 7.72 (d, J = 8.0 Hz, 2H), 7.53 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 7.9 Hz, 2H), 7.19 − 7.12 (m, 5H), 7.09 − 7.04 (m, 2H), 7.00 (d, J = 7.9 Hz, 2H), 6.90 (s, 1H), 6.85 (d, J = 8.3 Hz, 2H), 6.72 (d, J = 8.3 Hz, 2H), 4.99 (t, J = 2.9 Hz, 1H), 4.77 (t, J = 2.7 Hz, 1H), 4.69 (d, J = 14.1 Hz, 1H), 4.46 (d, J = 14.1 Hz, 1H), 2.42 (s, 6H), 2.34 (s, 3H); 13 C NMR (100 MHz, CDCl₃) (8, ppm) 164.4, 156.2, 143.7, 143.6, 143.3, 139.3, 136.4, 135.6, 134.9, 134.6, 132.4, 129.4, 129.2, 129.0, 128.7, 128.5, 128.4, 128.3, 127.72, 127.68, 123.3, 90.1, 81.3, 54.6, 21.8, 21.7, 21.6; HRMS (TOF MS ESI⁺) calculated for C₃₈H₃₆N₃O₅S₂ [M+H]⁺: 678.2091, found 678.2088.

Synthesis of 6: To a 10-mL oven-dried vial with a magnetic stirring bar, **3g** (58.8 mg), benzoic acid (24.4 mg, 0.20 mmol, 2.0 equiv.), and DCE (1.0 mL) were added, and the reaction mixture was stirred for 12 h at 70 °C. When the reaction was completed (monitored by TLC), the crude reaction mixture was purified by column chromatography on silica gel (Hexanes : EtOAc = 2:1) to give 48.7 mg pure product **6** in 83% yield as white solid, mp: 70-72 °C. 1 H NMR (400 MHz, CDCl₃) (δ , ppm) 7.79 (d, J = 4.3 Hz, 2H), 7.58 – 7.50 (m, 4H), 7.26 – 7.24 (m, 2H), 7.23 – 7.17 (m, 4H), 7.14 – 7.10 (m, 2H), 7.01 – 6.96 (m, 1H), 6.94 (s, 1H), 6.90 – 6.85 (m, 1H), 6.60 (s,


1H), 3.77 (s, 2H), 2.41 - 2.36 (m, 6H), 2.32 - 2.28 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 161.9, 149.1, 144.3, 144.2, 140.8, 136.4, 136.0, 135.9, 134.4, 131.0, 130.4, 129.9, 129.8, 129.6, 128.1, 127.3, 126.3, 125.1, 124.7, 122.7, 120.5, 28.0, 21.7, 21.6; HRMS (TOF MS ESI⁺) calculated for C₃₁H₃₀N₃O₅S₂ [M+H]⁺: 588.1621, found 588.1612.


Synthesis of 7: To a 10-mL oven-dried vial with a magnetic stirring bar, 6 (48.7 mg), Cs₂CO₃ (52.5 mg, 0.17 mmol, 2.0 equiv.) in MeCN (1.0 mL), was added a solution of BnBr (42.5 mg, 0. 25 mmol, 3.0 equiv.), and the reaction mixture was stirred for 6 h at 30 °C. When the reaction was completed (monitored by TLC), the crude reaction mixture was purified by column chromatography on silica gel (Hexanes : EtOAc = 3:1) to give 58.9 mg pure product 7 in 92% yield as white solid. ¹H NMR (400 MHz, CDCl₃) (δ , ppm) 7.79 (d, J = 7.7 Hz, 2H), 7.49 (d, J = 7.7 Hz, 2H), 7.37 (d, J = 7.8 Hz, 2H), 7.30 - 7.26 (m, 3H), 7.23 - 7.13 (m, 6H), 7.13 - 7.08 (m, 3H), 7.08 - 7.04 (m, 2H), 7.02 - 6.98 (m, 2H), 6.84 (d, J = 11.9 Hz, 1H), 6.59 (s, 1H), 6.45 (d, J = 8.8 Hz, 1H), 6.16 (s, 1H), 5.04 (d, J = 13.2 Hz, 1H), 4.60 – 4.49 (m, 2H), 4.05 (d, J = 13.2 Hz, 1H), 3.87 – 3.70 (m, 2H), 2.46 (s, 3H), 2.42 (s, 3H), 2.33 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) (δ , ppm) 161.2, 149.9, 144.7, 144.1, 140.5, 140.1, 139.2, 136.6, 135.5, 135.2, 135.1, 134.9, 129.8, 129.64, 129.58, 129.1, 128.9, 128.8, 128.6, 128.5, 128.4, 128.3, 128.1, 127.8, 127.6, 126.2, 125.3, 125.1, 124.6, 56.2, 54.6, 27.1, 22.8, 21.8, 21.6; HRMS (TOF MS ESI⁺) calculated for C₄₅H₄₂N₃O₅S₂ [M+H]⁺: 768.2560, found 768.2551.

Synthesis of 9: To a 10-mL oven-dried vial with a magnetic stirring bar, 3h (30.9 mg, 0.1 mmol, 1.0 equiv.), Rh₂(esp)₂ (0.5 mg, 1.0 mmol%) in DCM (1.0 mL), was added a solution of diazo compound 8 (54.8 mg, 0.25 mmol, 5.0 equiv.) in DCM (1.0 mL) at 0 °C via syringe pump in 2 hours, and the reaction mixture was stirred for 24 h at 20 °C. When the reaction was completed (monitored by TLC), the crude reaction mixture was purified by column chromatography on silica gel (Hexanes : EtOAc = 4:1) to give 55.9 mg pure product 9 in 69% yield as yellow solid, mp: 180-183 °C. ¹H NMR (400 MHz, DMSO) (δ, ppm) 11.34 (s, 1H), 10.31 (s, 1H), 7.71 – 7.66 (m, 4H), 7.59 - 7.55 (m, 4H), 7.51 - 7.47 (m, 2H), 7.44 - 7.39 (m, 1H), 7.35 - 7.32 (m, 1H), 7.31 - 7.26 (m, 3H), 7.12 - 7.09 (m, 3H), 7.08 - 7.06 (m, 1H), 7.06 - 7.02 (m, 3H), 7.02 - 6.98 (m, 2H), 6.73 (t, J = 7.0 Hz, 1H), 4.28 (s, 2H), 3.86 (s, 3H), 3.77 (s, 3H), 2.33 (s, 3H); ¹³C NMR (100 MHz, DMSO) (δ, ppm) 163.0, 162.5, 157.5, 151.9, 147.8, 140.8, 137.4, 135.8, 135.6, 134.9, 133.8, 132.4, 131.0, 130.6, 129.7, 129.1, 128.8, 128.4, 128.1, 125.5, 123.7, 121.7, 119.7, 118.8, 114.4, 114.1, 111.2, 105.2, 82.4, 55.7, 55.6, 21.0, 19.7; HRMS (TOF MS ESI⁺) calculated for C₄₅H₃₉N₄O₇S₂ [M+H]⁺: 811.2255, found 811.2246.

































90 80 f1 (ppm) 








$$SO_2Ar$$
 N
 $NHSO_2A$
 $3e$, $Ar = 4-CF_3Ph$



































































3.0



















































Single-Crystal X-ray Diffraction of 3g



Bond precision: C-C = 0.0094 A Wavelength=1.54184

Cell: a=15.9606(11) b=10.2207(10) c=18.4680(13)

alpha=90 beta=93.322(7) gamma=90

Temperature: 293 K

Calculated Reported 3007.6(4) Volume 3007.6(4) P 1 21/c 1 P 21/c Space group -P 2ybc -P 2ybc Hall group Moiety formula C31 H29 N3 O5 S2 Sum formula

Mr 587.69 587.69 1.298 2 4 4 4 4 4 4 4 4 1.966 1.290 1.232.0 1232.0

F000' 1238.10 h,k,lmax 19,12,23 19,12,22 Nref 6113 5680 Tmin,Tmax 0.954,0.981 0.755,1.000

Tmin' 0.943

Correction method= # Reported T Limits: Tmin=0.755 Tmax=1.000 AbsCorr = MULTI-SCAN

Data completeness= 0.929 Theta(max) = 74.019

S = 0.984 Npar= 373

References

1 (*a*) J. Qin, T. Zhou, L. Tang, H. Zuo, H. Yu, G. Wu, Y. Wu, R. Liao, and F. Zhong, *Angew. Chem. Int. Ed.*, 2022, **61**, e202205159; (*b*) W. Bao, Y. Chen, Y. Liu, S. Xiang and B. Tan, *Chin. J. Chem.*, 2024, **42**, 731-735.

2 Y. Wang, K. Ji, S. Lan and L. Zhang, *Angew. Chem. Int. Ed.*, 2012, **51**, 1915-1918.